Update Breast Cancer 2020 Part 1 - Early Breast Cancer

Standard

Update Breast Cancer 2020 Part 1 - Early Breast Cancer : Consolidation of Knowledge About Known Therapies. / Schneeweiss, Andreas; Hartkopf, Andreas D; Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Ettl, Johannes; Belleville, Erik; Huober, Jens; Thill, Marc; Fasching, Peter A; Kolberg, Hans-Christian; Pöschke, Patrik; Welslau, Manfred; Overkamp, Friedrich; Tesch, Hans; Fehm, Tanja N; Lüftner, Diana; Schütz, Florian.

In: GEBURTSH FRAUENHEILK, Vol. 80, No. 3, 03.2020, p. 277-287.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Schneeweiss, A, Hartkopf, AD, Müller, V, Wöckel, A, Lux, MP, Janni, W, Ettl, J, Belleville, E, Huober, J, Thill, M, Fasching, PA, Kolberg, H-C, Pöschke, P, Welslau, M, Overkamp, F, Tesch, H, Fehm, TN, Lüftner, D & Schütz, F 2020, 'Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies', GEBURTSH FRAUENHEILK, vol. 80, no. 3, pp. 277-287. https://doi.org/10.1055/a-1111-2431

APA

Schneeweiss, A., Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Belleville, E., Huober, J., Thill, M., Fasching, P. A., Kolberg, H-C., Pöschke, P., Welslau, M., Overkamp, F., Tesch, H., Fehm, T. N., Lüftner, D., & Schütz, F. (2020). Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. GEBURTSH FRAUENHEILK, 80(3), 277-287. https://doi.org/10.1055/a-1111-2431

Vancouver

Bibtex

@article{5c87fdb23b0d43788be6982a3183306e,
title = "Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies",
abstract = "This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.",
author = "Andreas Schneeweiss and Hartkopf, {Andreas D} and Volkmar M{\"u}ller and Achim W{\"o}ckel and Lux, {Michael P} and Wolfgang Janni and Johannes Ettl and Erik Belleville and Jens Huober and Marc Thill and Fasching, {Peter A} and Hans-Christian Kolberg and Patrik P{\"o}schke and Manfred Welslau and Friedrich Overkamp and Hans Tesch and Fehm, {Tanja N} and Diana L{\"u}ftner and Florian Sch{\"u}tz",
year = "2020",
month = mar,
doi = "10.1055/a-1111-2431",
language = "English",
volume = "80",
pages = "277--287",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2020 Part 1 - Early Breast Cancer

T2 - Consolidation of Knowledge About Known Therapies

AU - Schneeweiss, Andreas

AU - Hartkopf, Andreas D

AU - Müller, Volkmar

AU - Wöckel, Achim

AU - Lux, Michael P

AU - Janni, Wolfgang

AU - Ettl, Johannes

AU - Belleville, Erik

AU - Huober, Jens

AU - Thill, Marc

AU - Fasching, Peter A

AU - Kolberg, Hans-Christian

AU - Pöschke, Patrik

AU - Welslau, Manfred

AU - Overkamp, Friedrich

AU - Tesch, Hans

AU - Fehm, Tanja N

AU - Lüftner, Diana

AU - Schütz, Florian

PY - 2020/3

Y1 - 2020/3

N2 - This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.

AB - This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.

U2 - 10.1055/a-1111-2431

DO - 10.1055/a-1111-2431

M3 - SCORING: Journal article

C2 - 32139917

VL - 80

SP - 277

EP - 287

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 3

ER -